#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	1944	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2348	159.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1579	1579	C	266	C	164	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3866	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3544	205.9	0	.	n	.	0	T695C	SNP	695	695	T	983	983	C	288	C	181	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3866	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3544	205.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1625	1625	A	188	A	128	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3866	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3544	205.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2259	2259	C	204	C	132	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3866	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3544	205.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2885	2885	T	213	T	131	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3866	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3544	205.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2333	2333	A	222	A	139	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	432	92.01	folP.l6.c4.ctg.1	563	11.7	0	.	p	.	0	R147Q	NONSYN	439	441	CGG	31	33	CAG	13;11;11	C;A;G	1;1;1	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	432	92.01	folP.l6.c4.ctg.1	563	11.7	0	.	p	.	0	T152N	NONSYN	454	456	ACC	46	48	AAC	8;8;8	A;A;C	1;1;1	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	432	92.01	folP.l6.c4.ctg.1	563	11.7	0	.	p	.	0	D155I	NONSYN	463	465	GAC	55	57	ATT	8;8;8	A;T;T	1;1;1	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	432	92.01	folP.l6.c4.ctg.1	563	11.7	0	.	p	.	0	G194_F195insSG	INS	580	580	G	172	172	G	8	G	6	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	432	92.01	folP.l6.c4.ctg.1	563	11.7	0	.	p	.	0	M229T	NONSYN	685	687	ATG	283	285	ACG	11;11;11	A;C;G	6;7;7	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	432	92.01	folP.l6.c4.ctg.1	563	11.7	0	.	p	.	0	A237T	NONSYN	709	711	GCG	307	309	ACC	15;15;15	A;C;C	8;8;8	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	432	92.01	folP.l6.c4.ctg.1	563	11.7	0	.	p	.	0	S253A	NONSYN	757	759	TCC	355	357	GCT	17;17;17	G;C;T	11;11;11	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	432	92.01	folP.l6.c4.ctg.1	563	11.7	1	SNP	p	R228S	1	.	.	682	684	AGC	280	282	AGC	11;11;11	A;G;C	7;6;7	folP.WHO_M_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	280	96.43	folP.l6.c4.ctg.2	288	8.2	0	.	p	.	0	R7Q	NONSYN	19	21	CGG	27	29	CAG	7;7;7	C;A;G	2;2;2	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	280	96.43	folP.l6.c4.ctg.2	288	8.2	0	.	p	.	0	S68L	NONSYN	202	204	TCG	210	212	TTG	9;9;9	T;T;G	4;5;5	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	280	96.43	folP.l6.c4.ctg.2	288	8.2	0	.	p	.	0	F72Y	NONSYN	214	216	TTC	222	224	TAT	9;9;9	T;A;T	6;5;6	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	280	96.43	folP.l6.c4.ctg.2	288	8.2	0	.	p	.	0	P74S	NONSYN	220	222	CCG	228	230	TCG	9;9;9	T;C;G	6;6;6	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	280	96.43	folP.l6.c4.ctg.2	288	8.2	0	.	p	.	0	A89V	NONSYN	265	267	GCG	273	275	GTG	6;6;6	G;T;G	5;5;5	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	512	60	folP	852	280	96.43	folP.l6.c4.ctg.2	288	8.2	0	.	p	.	0	A90V	NONSYN	268	270	GCG	276	278	GTT	6;6;6	G;T;T	5;5;5	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	320	gyrA	2751	402	100.0	gyrA.l15.c4.ctg.1	634	20.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	320	gyrA	2751	2309	99.83	gyrA.l15.c4.ctg.2	2372	19.8	1	SNP	p	S91F	0	.	.	271	273	TCC	334	336	TCC	16;16;16	T;C;C	10;9;11	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	320	gyrA	2751	2309	99.83	gyrA.l15.c4.ctg.2	2372	19.8	1	SNP	p	D95N	0	.	.	283	285	GAC	346	348	GAC	15;15;15	G;A;C	9;9;9	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	320	gyrA	2751	2309	99.83	gyrA.l15.c4.ctg.2	2372	19.8	1	SNP	p	D95G	0	.	.	283	285	GAC	346	348	GAC	15;15;15	G;A;C	9;9;9	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	110	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1226	19.2	1	SNP	p	G45D	1	.	.	133	135	GAC	485	487	GAC	42;42;42	G;A;C	26;27;28	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	86	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	745	21.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	312	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2782	19.9	1	SNP	p	D86N	0	.	.	256	258	GAC	504	506	GAC	25;25;25	G;A;C	17;18;18	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	312	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2782	19.9	1	SNP	p	S87I	0	.	.	259	261	AGT	507	509	AGT	25;25;25	A;G;T	17;18;18	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	312	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2782	19.9	1	SNP	p	S87W	0	.	.	259	261	AGT	507	509	AGT	25;25;25	A;G;T	17;18;18	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	312	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2782	19.9	1	SNP	p	S87R	0	.	.	259	261	AGT	507	509	AGT	25;25;25	A;G;T	17;18;18	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	312	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2782	19.9	1	SNP	p	S88P	0	.	.	262	264	TCC	510	512	TCC	25;28;28	T;C;C	18;20;19	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	290	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2741	20.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1748	1750	GGC	14;14;14	G;G;C	11;11;11	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	342	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2063	30.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1222	1224	GCA	41;41;41	G;C;A,G	28;27;27,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	342	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2063	30.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1225	1227	ATC	41;41;41	A;T;C	27;28;27	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	342	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2063	30.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1237	1239	GTG	41;41;41	G;T;G	27;26;26	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	342	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2063	30.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1237	1239	GTG	41;41;41	G;T;G	27;26;26	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	342	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2063	30.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1741	1743	ACC	14;13;14	A;C;C	7;8;7	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	342	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2063	30.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1795	1797	GCG	12;12;12	G;C;G	10;10;10	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	342	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2063	30.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1795	1797	GCG	12;12;12	G;C;G	10;10;10	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	342	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2063	30.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1918	1920	GGC	11;12;12	G;G;C	7;8;7	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	342	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2063	30.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1927	1929	GGC	10;10;10	G;G;C	6;5;5	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	342	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2063	30.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1945	1947	CCG	8;8;7	C;C;G	4;5;3	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	598	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3129	35.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1626	1628	CTG	27;27;27	C;T;G	17;17;17	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	190	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1594	21.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	518	518	C	15	C	10	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	G38E	NONSYN	112	114	GGA	299	301	GAA	16;16;16	G;A;A	12;12;12	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	305	307	CAG	15;15;15	C;A;G	11;11;12	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	S46G	NONSYN	136	138	AGC	323	325	GGC	13;13;13	G;G;C	10;10;11	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	329	331	GGA	13;13;13	G;G;A	9;11;11	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	T87A	NONSYN	259	261	ACT	446	448	GCT	18;18;18	G;C;T	15;16;14	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	T89S	NONSYN	265	267	ACC	452	454	AGC	20;20;20	A;G;C	16;13;15	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	.	MULTIPLE	358	359	AA	544	545	CG	18;18	C;G	13;14	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	.	MULTIPLE	361	362	GA	547	549	CAG	19;19;19	C;A;G	14;14;16	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	N122K	NONSYN	364	366	AAC	551	553	AAA	19;19;19	A;A;A	14;16;13	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	K143E	NONSYN	427	429	AAA	614	616	GAA	21;21;21	G;A;A	15;16;13	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	V151A	NONSYN	451	453	GTA	638	640	GCA	24;24;24	G;C;A	15;15;13	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	A215T	NONSYN	643	645	GCT	830	832	ACT	45;45;43	A;C;T	29;30;27	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	I218M	NONSYN	652	654	ATA	839	841	ATG	33;34;34	A;T;G	23;24;23	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	T256A	NONSYN	766	768	ACA	953	955	GCA	37;37;34	G;C;A	22;23;21	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	W257T	NONSYN	769	771	TGG	956	958	ACG	34;34;34	A;C;G	22;22;20	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	S258G	NONSYN	772	774	AGT	959	961	GGG	34;32;32	G;G;G	21;20;21	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	A259V	NONSYN	775	777	GCT	962	964	GTT	32;32;31	G;T;T	20;19;20	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1022	1024	GTA	45;45;45	G;T;A	27;27;28	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1061	1063	ACT	48;49;49	A;C;T	29;30;30	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1067	1069	GAT	52;52;52	G;A,T;T	31;31,1;31	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1079	1081	CAC	49;47;47	C;A;C	30;27;29	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	1	SNP	p	G120K	1	.	.	358	360	AAG	544	546	CGG	18;18;19	C;G;G	13;14;16	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	1	SNP	p	A121D	1	.	.	361	363	GAC	547	550	CGC	19;19;19	C;G;C	14;16;16	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	180	porB1b	1047	1047	96.95	porB1b.l15.c4.ctg.1	1531	22.1	1	SNP	p	D121N	0	.	.	361	363	GAC	547	550	CGC	19;19;19	C;G;C	14;16;16	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	994	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4748	40.2	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1760	1762	CAT	47;47;47	C;A;T	31;31;32	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	92	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1064	18.5	1	SNP	p	V57M	1	.	.	169	171	ATG	487	489	ATG	38;38;39	A;T;G	26;26;27	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
